CN107106553A - 用于干眼的动物模型和此类动物的使用方法 - Google Patents

用于干眼的动物模型和此类动物的使用方法 Download PDF

Info

Publication number
CN107106553A
CN107106553A CN201580065760.3A CN201580065760A CN107106553A CN 107106553 A CN107106553 A CN 107106553A CN 201580065760 A CN201580065760 A CN 201580065760A CN 107106553 A CN107106553 A CN 107106553A
Authority
CN
China
Prior art keywords
candidate agents
hyoscine
rodent
eye
benzalkonium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580065760.3A
Other languages
English (en)
Chinese (zh)
Inventor
袁明
呼莹
曹景泰
卡梅罗·罗马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN107106553A publication Critical patent/CN107106553A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Educational Technology (AREA)
  • Pure & Applied Mathematics (AREA)
  • Medical Informatics (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Theoretical Computer Science (AREA)
  • Algebra (AREA)
  • Business, Economics & Management (AREA)
CN201580065760.3A 2014-12-02 2015-12-01 用于干眼的动物模型和此类动物的使用方法 Pending CN107106553A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086263P 2014-12-02 2014-12-02
US62/086,263 2014-12-02
PCT/US2015/063084 WO2016089807A1 (en) 2014-12-02 2015-12-01 Animal model for dry eye and methods of use of such animals

Publications (1)

Publication Number Publication Date
CN107106553A true CN107106553A (zh) 2017-08-29

Family

ID=55024246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580065760.3A Pending CN107106553A (zh) 2014-12-02 2015-12-01 用于干眼的动物模型和此类动物的使用方法

Country Status (14)

Country Link
US (1) US20170360013A1 (cg-RX-API-DMAC10.html)
EP (1) EP3226853B1 (cg-RX-API-DMAC10.html)
JP (1) JP6692808B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170100483A (cg-RX-API-DMAC10.html)
CN (1) CN107106553A (cg-RX-API-DMAC10.html)
AU (1) AU2015355169A1 (cg-RX-API-DMAC10.html)
CA (1) CA2967432A1 (cg-RX-API-DMAC10.html)
ES (1) ES2759729T3 (cg-RX-API-DMAC10.html)
IL (1) IL252077A0 (cg-RX-API-DMAC10.html)
MX (1) MX2017007295A (cg-RX-API-DMAC10.html)
RU (1) RU2706787C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201703572SA (cg-RX-API-DMAC10.html)
WO (1) WO2016089807A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201703052B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909998T3 (es) * 2016-10-14 2022-05-11 I Com Medical Gmbh Método para establecer, restablecer y preservar la homeostasis de la superficie ocular
US12303527B2 (en) 2018-04-18 2025-05-20 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
KR102429281B1 (ko) * 2020-05-25 2022-08-05 (주)노바셀테크놀로지 신규 안구건조증 치료용 약학적 조성물
CN113519461A (zh) * 2021-07-06 2021-10-22 江西中洪博元生物技术有限公司 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用
WO2023215261A1 (en) * 2022-05-02 2023-11-09 Ocular Services On Demand, Llc Mammalian eye models

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2384679A1 (en) * 1999-09-08 2001-03-15 Srinivasan Venkateshwaran Using quaternary ammonium salts for transdermal drug delivery
EP2598131A1 (fr) * 2010-07-29 2013-06-05 Laboratoires Fournier S.A. Composes pour le traitement/la prevention des maladies inflammatoires oculaires

Also Published As

Publication number Publication date
RU2017118978A (ru) 2019-01-09
ES2759729T3 (es) 2020-05-12
RU2706787C2 (ru) 2019-11-21
EP3226853A1 (en) 2017-10-11
KR20170100483A (ko) 2017-09-04
SG11201703572SA (en) 2017-05-30
CA2967432A1 (en) 2016-06-09
US20170360013A1 (en) 2017-12-21
IL252077A0 (en) 2017-07-31
RU2017118978A3 (cg-RX-API-DMAC10.html) 2019-06-04
MX2017007295A (es) 2018-03-12
JP6692808B2 (ja) 2020-05-13
EP3226853B1 (en) 2019-09-04
AU2015355169A1 (en) 2017-05-25
WO2016089807A1 (en) 2016-06-09
ZA201703052B (en) 2019-03-27
JP2018500546A (ja) 2018-01-11

Similar Documents

Publication Publication Date Title
Haller et al. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials
Bhisitkul et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study
Abbott et al. Evaluation of retinal nerve fiber layer thickness and axonal transport 1 and 2 weeks after 8 hours of acute intraocular pressure elevation in rats
Sheppard et al. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study
TWI658828B (zh) 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
Keane–Myers et al. Prevention of allergic eye disease by treatment with IL-1 receptor antagonist
Lyzogubov et al. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization
Merrill et al. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) program
JP6692808B2 (ja) ドライアイ用動物モデルおよびこうした動物の使用方法
Avci et al. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits
Lee et al. Tissue response to implanted Ahmed glaucoma valve with adjunctive amniotic membrane in rabbit eyes
Kim et al. A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells
Woodward et al. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva
Gedik et al. The assesment of retina and optic disc vascular structures in people who received CoronaVac vaccine
Liang et al. In vivo confocal microscopy and ex vivo flow cytometry: new tools for assessing ocular inflammation applied to rabbit lipopolysaccharide-induced conjunctivitis
EP2870971B1 (en) Drug for preventing/treating ocular disease
Yang et al. Morphological, immunohistochemical and quantitative studies of murine brain mast cells after mating
CN108348544B (zh) 用于抑制血管生成的含有纳米颗粒-玻璃体基蛋白质复合物作为活性成分的组合物及其用途
Burns et al. Selective neovascularization of the retinal pigment epithelium in rat photoreceptor degeneration in vivo
Hong et al. Substance-P blocks degeneration of retina by stimulating migration and proliferation of retinal pigmented epithelial cells
Sun et al. Experimental anterior ischemic optic neuropathy in diabetic mice exhibited severe retinal swelling associated with VEGF elevation
KR20220051791A (ko) Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물
Muellerleile et al. Serum vascular endothelial growth factor changes and safety after topical anti‐human VEGF antibody bevacizumab in healthy dogs
RU2558991C1 (ru) Способ моделирования пролиферативной витреоретинопатии у крыс
Павлова et al. Омализумаб в лечении сезонных обострений тяжёлого аллергического ринита

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20210604

AD01 Patent right deemed abandoned